Streetbeat News

Analyst Ratings

ABT

Analyst ratings for Abbott Laboratories (NYSE:ABT) show a positive trend with 7 analysts offering diverse opinions over the last three months. The average 12-month price target has been raised to $129.43 from $125.00, indicating a 3.54% increase. Recent actions by analysts include ratings from 'Buy' to 'Outperform' with price target adjustments reflecting optimism about the company's performance. Abbott's financial metrics such as revenue growth, net margin, ROE, ROA, and debt management are highlighted, showcasing its strong market position and financial health.

Portfolio Pulse from Benzinga Insights

April 03, 2024 | 4:00 pm

BSX

Argus Research analyst John Eade maintains a Buy rating on Boston Scientific (NYSE:BSX) and raises the price target from $69 to $80.

Portfolio Pulse from Benzinga Newsdesk

April 03, 2024 | 4:00 pm

SYK

Citigroup analyst Joanne Wuensch has maintained a Buy rating on Stryker (NYSE:SYK) and increased the price target from $362 to $406.

Portfolio Pulse from Benzinga Newsdesk

April 03, 2024 | 3:59 pm

APTO

Piper Sandler analyst Edward Tenthoff has maintained an Overweight rating on Aptose Biosciences (NASDAQ:APTO) with a price target of $5.

Portfolio Pulse from Benzinga Newsdesk

April 03, 2024 | 3:58 pm

AFG

Citigroup analyst Charlie Lederer has maintained a Buy rating on American Financial Group (AFG) and increased the price target from $139 to $145 on March 25.

Portfolio Pulse from Benzinga Newsdesk

April 03, 2024 | 3:58 pm

COCH

Envoy Medical's shares surged following the announcement of financial results that exceeded expectations. Additionally, Lake Street has reaffirmed its Buy rating on the stock, doubling the price target from $3 to $6.

Portfolio Pulse from Benzinga Newsdesk

April 03, 2024 | 3:57 pm

NVRO

Citigroup analyst Joanne Wuensch has maintained a Neutral rating on Nevro (NYSE:NVRO) and reduced the price target from $18 to $16.

Portfolio Pulse from Benzinga Newsdesk

April 03, 2024 | 3:56 pm

GILD

Wells Fargo analyst Mohit Bansal has maintained an Equal-Weight rating on Gilead Sciences (NASDAQ:GILD) and lowered the price target from $84 to $78 on March 4.

Portfolio Pulse from Benzinga Newsdesk

April 03, 2024 | 3:55 pm

AAPL

ADP

AMZN

GOOG

META

MSFT

NVDA

QQQ

SPY

TLT

TSLA

Wall Street is increasingly recognizing the risks in the stock market, with a focus on the iShares 20+ Year Treasury Bond ETF (TLT) showing a downward trend, indicating rising market risk. Investors are looking towards a dovish stance from Powell to stabilize the market. ADP's employment data exceeded expectations, suggesting a strong jobs market. Early trading shows positive money flows in META, neutral in AAPL and MSFT, and negative in AMZN, GOOG, NVDA, TSLA, SPY, and QQQ. Silver and gold are seeing aggressive buying, with oil also up following a draw in crude inventories.

Portfolio Pulse from The Arora Report

April 03, 2024 | 3:53 pm